Autoantibodies Can Predict Development of Severe COVID by Up To 92.8%

September 16, 2021

A study published last week in Life Science Alliance analyzed blood samples from 115 patients hospitalized with SARS-CoV-2 and 42 uninfected controls and discovered the presence of autoantibodies in 36% of COVID-19 hospital patients. A strong association was made between the presence of these self-attacking immune system defense molecules and the more severe COVID-19 cases. Researchers focused on anti-DNA and anti-PS antibodies, determining that these antibodies could predict the later development of severe disease by 85.7% and 92.8%, respectively.

The authors went on to conclude that “anti-DNA and anti-PS autoantibodies may play an important role in the pathogenesis of COVID-19 and could be developed as predictive biomarkers for disease severity and specific clinical manifestations.” Their observations suggest that the most severe forms of disease observed in COVID-19 patients may be a result of the host response to infection, rather than a direct consequence of viral cytopathic effect (structural changes in host cells that are caused by viral invasion), which is similar to what occurs in some autoimmune diseases.





Join Our Community!Stay Informed. Stay Hopeful.

Sign up for periodic emails with resources, insights, and updates on autoimmune disease and living with chronic illness.

By adding your phone number, you agree to receive text message updates. Msg & data rates may apply.